-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
IUI1:F:F- (EUR)
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 414.05Change
+2.25 (+0.55)%Market Cap
USD 143.32BVolume
21.00Verdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 414.05Change
+2.25 (+0.55)%Market Cap
USD 143.32BVolume
21.00Verdict
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ESL:F | EssilorLuxottica Société ano.. |
-1.80 (-0.88%) |
USD 95.80B |
ESLC:F | ESSILORLUXOTTICA 1/2/O.N. |
-2.00 (-1.96%) |
USD 93.89B |
BOX:F | Becton Dickinson and Company |
-1.30 (-0.60%) |
USD 64.33B |
HYB0:F | HOYA CORP. ADR/ 1 O.N. |
N/A |
USD 38.45B |
HYB:F | HOYA Corporation |
-0.35 (-0.32%) |
USD 38.30B |
RME:F | ResMed Inc |
+3.50 (+1.97%) |
USD 26.35B |
CBH:F | COLOPLAST SP.ADR 1/10 DK1 |
-0.10 (-0.92%) |
USD 25.53B |
CBHD:F | Coloplast A/S |
-1.00 (-0.88%) |
USD 25.50B |
RMEA:F | Resmed Inc DRC |
+0.20 (+1.14%) |
USD 25.27B |
TUO:F | Terumo Corporation |
N/A |
USD 22.79B |
N/A
Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 34.89% | 94% | A | 89% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 34.89% | 86% | B+ | 82% | B | ||
Trailing 12 Months | |||||||
Capital Gain | 35.75% | 93% | A | 83% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 35.75% | 85% | B | 75% | C | ||
Trailing 5 Years | |||||||
Capital Gain | -9.35% | 45% | F | 37% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -9.35% | 37% | F | 26% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 2.75% | 60% | D- | 56% | F | ||
Dividend Return | 2.75% | 54% | F | 50% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 44.14% | 20% | F | 23% | F | ||
Risk Adjusted Return | 6.24% | 54% | F | 45% | F | ||
Market Capitalization | 143.32B | 100% | F | 99% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.